# A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Study · id `cardio:ct-nct03697109` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03697109](<https://clinicaltrials.gov/study/NCT03697109>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03697109

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

## Technical summary

Registry record NCT03697109. Randomized; triple masking; primary purpose treatment. Start 2018-11-15 (actual); primary completion 2024-04-08 (actual). Results posted on 2025-04-24.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 152 participants (enrolled count; ClinicalTrials.gov record NCT03697109, source copy `cardio:ctgov-nct03697109-2025-07-16`, retrieved 2026-10-26)
- Started: 2018-11-15 (actual) (ClinicalTrials.gov record NCT03697109, source copy `cardio:ctgov-nct03697109-2025-07-16`, retrieved 2026-10-26)
- Primary completion: 2024-04-08 (actual) (ClinicalTrials.gov record NCT03697109, source copy `cardio:ctgov-nct03697109-2025-07-16`, retrieved 2026-10-26)
- Completion: 2024-04-15 (actual) (ClinicalTrials.gov record NCT03697109, source copy `cardio:ctgov-nct03697109-2025-07-16`, retrieved 2026-10-26)
- Results first posted: 2025-04-24 (ClinicalTrials.gov record NCT03697109, source copy `cardio:ctgov-nct03697109-2025-07-16`, retrieved 2026-10-26)
- Countries: United States; Austria; Bulgaria; Canada; Germany; Israel; Italy; Netherlands; Poland; Romania; Spain (ClinicalTrials.gov record NCT03697109, source copy `cardio:ctgov-nct03697109-2025-07-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03697109-2025-07-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
- Acronym: GRACE
- Condition: Cushing Syndrome
- Intervention (Drug): Relacorilant
- Intervention (Other): Placebo
- Lead sponsor: Corcept Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Corcept Therapeutics (`cardio:org-corcept-therapeutics`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study (`cardio:pubmed-41730814`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 12f194b3d21e89c0f80e089472f8d433f06519ee1907611340a789025968daa6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
